Stocks
Zynerba Pharmaceuticals (ZYNE) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 9 504% | 15 754% | 8 007% | 45 038% | 13 692% | 12 348% | |||
| Changes by years, y/y, % | -10 266pp | +6 250pp | -7 747pp | +37 031pp | -31 346pp | -7.1% | |||
Zynerba Pharmaceuticals. R&D/CAPEX, %
Zynerba Pharmaceuticals. R&D/CAPEX, changes, pp
Zynerba Pharmaceuticals (ZYNE) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2022Q2 | 2022Q3 | 2022Q4 | 2023Q1 | 2023Q2 | LTM ? | |||
| R&D/CAPEX, % | 5 299% | 73 885% | 7 904% | 85 359% | 12 348% | |||
| Changes by years, y/y, % | -11 461pp | -2 069pp | ||||||
| Changes by quarters, q/q, % | -9 973pp | +68 586pp | -65 981pp | +77 455pp | ||||
